Oct 19 (Reuters) - Valeant Pharmaceuticals International Inc (N:VRX)
VRX.TO, which is under fire for massive price hikes of
its two heart drugs, reported a 36 percent rise in quarterly
revenue, as sales of dermatology products rose in the United
States.
Net income attributable to the Canadian drugmaker fell to
$49.5 million, or 14 cents per share, for the third quarter
ended Sept. 30, from $275.4 million, or 81 cents per share, a
year earlier.
Revenue rose to $2.79 billion from $2.06 billion.